ImmVirX

Our vision is to be a global, best-in-class immuno-oncology company that creates impactful drugs for patients with the highest medical needs. Founded in Canada in 2015, Virogin aims to unleash synergy between oncolytic virotherapy and mRNA vaccines in the battle against cancer. We have developed two platforms: (1) innovative HSV-1 based oncolytic virus and (2) mRNA-based (including self-amplifying RNA/saRNA) therapeutics, aiming to elicit robust and durable anti-tumor immune response against solid tumors.

XVir® Therapeutics GmbH is a biopharmaceutical company, which provides YB-1 dependent oncolytic adenoviruses for oncolytic immunotherapy based on selective lysis of tumor cells and concomitant systemic anti-cancer immune response.

Vir’s core capabilities include our deep immunology and virology expertise, our proven world-class monoclonal antibody platform with AI-led protein engineering capabilities, as well as our T cell-based viral vector platform. Vir has built a broad pipeline with several ongoing trials – including two late-stage programs in chronic hepatitis delta and chronic hepatitis B – that we believe will support near- and long-term growth, along with multiple potential INDs in the next 12-24 months. If you share our goal of addressing the unmet needs of patients around the world, please visit our careers page for open positions. Our growth and pursuit of scientific innovation is fueled by our leading monoclonal antibody (mAb) platform that has a proven track record and is further strengthened by our artificial intelligence-led mAb optimization and engineering capabilities. Our ability to develop impactful medicines for major public health challenges is a testament to the company’s deep knowledge of immunology and our ability to understand the interplay between viruses and the human immune system.”. We have an industry-leading management team and Board of Directors with significant immunology and infectious diseases experience, including a proven track record of progressing product candidates from early-stage research through clinical development, and worldwide regulatory approval and commercialization. We offer the opportunity to do challenging, rewarding work as part of our world class teams in the U.S.

ViraTherapeutics is a distinct unit of the Discovery Research organization of the Boehringer Ingelheim group of companies. ViraTherapeutics specializes in the development of highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. ViraTherapeutics currently performs preclinical safety and efficacy studies for our modified Vesicular Stomatitis Virus (VSV-GP) and aims to conduct first clinical trials in cancer patients in the near future. We are committed to developing new treatments for people living with cancer and improving their quality of life. Take your chance and check our recent job offers.

Our vision is to create a wave of potentially transformative, first-in-class immunotherapeutics designed to engage the body's immune system to both recognize and fight off infectious diseases and cancer. We are leveraging our VLV platform to develop a portfolio of products against diseases of high unmet need. Developed novel AVIDIO platform that delivers multiple transgenesArtificial Virus for Infectious Diseases & Immuno-Oncology.

Virion Therapeutics is a clinical-stage company developing novel T cell-based immunotherapies for cancer and chronic infectious diseases.